Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced that its
Special Meeting of Stockholders, scheduled for and convened on
February 6, 2018, has been adjourned to provide the Company’s
stockholders additional time to consider and vote
FOR Aviragen’s proposed merger with Vaxart, Inc.
Aviragen intends to reconvene the Special Meeting on February 9,
2018 at 12:00 pm EST.
The Aviragen Board of Directors unanimously recommends that
stockholders vote FOR the proposals necessary to
approve the proposed merger. Stockholders of record at the close of
business on January 2, 2018 are entitled to and are being requested
to vote. If a stockholder has already submitted their proxy card
and does not wish to change their vote, no further action is
required at this time.
Aviragen encourages stockholders that have not yet voted their
shares to vote by 11:59 pm EST on February 8, 2018. Each vote is
extremely important, no matter how many or how few shares are
owned. The affirmative vote of the holders of a majority of the
shares of Aviragen common stock properly cast at the Aviragen
Special Meeting, presuming a quorum is present, is required to
approve the proposed merger. Please take a moment to vote
FOR the proposals necessary to approve the
proposed merger today – by telephone, by Internet or by signing,
dating and returning the WHITE proxy card. Please
discard any BLUE proxy card you may receive from
the CAS Group.
Stockholders with questions or requiring assistance voting their
shares should contact Aviragen’s proxy solicitor, D.F. King &
Co., Inc., toll-free at (800) 967-5074. Each vote is extremely
important, no matter how many or how few shares are owned.
About Aviragen Therapeutics
Aviragen Therapeutics is focused on the discovery and
development of the next generation of direct-acting antivirals to
treat infections that have limited therapeutic options and affect a
significant number of patients globally. It has three Phase 2
clinical stage compounds: BTA074 (teslexivir), an antiviral
treatment for condyloma caused by human papillomavirus types 6 and
11; vapendavir, a capsid inhibitor for the prevention or treatment
of rhinovirus (RV) upper respiratory infections; and BTA585
(enzaplatovir), a fusion protein inhibitor in development for the
treatment of respiratory syncytial virus infections. Aviragen also
receives royalties from marketed influenza products, Relenza® and
Inavir®. For additional information, please visit
www.aviragentherapeutics.com.
Aviragen Therapeutics® is a registered trademark. Relenza® is a
registered trademark of GlaxoSmithKline Pharmaceuticals, Ltd., and
Inavir® is a registered trademark of Daiichi Sankyo Company,
Ltd.
Forward Looking Statements
This press release contains forward-looking statements about
Aviragen Therapeutics, Inc. and Vaxart Inc., and their respective
businesses, business prospects, strategy and plans, including but
not limited to statements regarding anticipated preclinical and
clinical drug development activities, timelines and market
opportunities; the combined company being well-funded to advance
its programs; the potential of Vaxart’s flu vaccine to produce
better efficacy and in a timely manner; and the combined company’s
ability to accelerate development of Vaxart’s vaccine candidates
and generate near and long term value for stockholders. All
statements other than statements of historical facts included in
this press release are forward looking statements. The words
“anticipates,” “may,” “can,” “plans,” “believes,” “estimates,”
“expects,” “projects,” “intends,” “likely,” “will,” “should,” “to
be,” and any similar expressions or other words of similar meaning
are intended to identify those assertions as forward looking
statements. These forward looking statements involve
substantial risks and uncertainties that could cause actual results
to differ materially from those anticipated, including, without
limitation: the risk that the conditions to the closing of the
merger are not satisfied, the failure to timely or at all obtain
stockholder approval for the merger; uncertainties as to the timing
of the consummation of the merger and the ability of each of
Aviragen and Vaxart to consummate the merger; risks related to
Aviragen’s ability to correctly estimate its operating expenses and
its expenses associated with the merger; risks related to the
market price of Aviragen’s common stock relative to the exchange
ratio; the ability of Aviragen or Vaxart to protect their
respective intellectual property rights; competitive responses to
the merger; unexpected costs, charges or expenses resulting from
the merger; and potential adverse reactions or changes to business
relationships resulting from the announcement or completion of the
merger. The vaccine candidates that Vaxart develops may not
progress through clinical development or receive required
regulatory approvals within expected timelines or at all. In
addition, future clinical trials may not confirm any safety,
potency or other product characteristics described or assumed in
this press release and such vaccine candidates may not successfully
commercialized. Additional factors that may cause actual
results to differ materially from such forward looking statements
include those identified under the caption “Risk Factors” in the
documents filed by Aviragen with the Securities and Exchange
Commission from time to time, including its Proxy/Prospectus on
Form S-4, Annual Reports on Form 10-K, Quarterly Reports on Form
10-Q, and Current Reports on Form 8-K. You are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. Except to the
extent required by applicable law or regulation, neither Aviragen
nor Vaxart undertakes any obligation to update the forward-looking
statements included in this press release to reflect subsequent
events or circumstances.
Additional Information About the Merger and Where to
Find It
In connection with the proposed strategic merger, Aviragen and
Vaxart have filed relevant materials with the Securities and
Exchange Commission, or the SEC, including a registration statement
on Form S-4, as amended, that contains a prospectus and a joint
proxy statement. Investors may obtain the proxy
statement/prospectus, as well as other filings containing important
information about Aviragen, Vaxart and the merger, free of charge
at the SEC’s web site (www.sec.gov). In addition, investors and
security holders may obtain free copies of the documents filed with
the SEC by Aviragen by directing a written request to: Aviragen
Therapeutics, Inc. 2500 Northwinds Parkway, Suite 100, Alpharetta,
GA 30009, Attention: Corporate Secretary or delivered via email to
investors@aviragentherapeutics.com. Investors and security holders
are urged to read the proxy statement/prospectus and the other
relevant materials before making any voting or investment decision
with respect to the merger.
This communication shall not constitute an offer to sell or the
solicitation of an offer to sell or the solicitation of an offer to
buy any securities, nor shall there be any sale of securities in
any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offering of securities
shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act of 1933, as
amended.
Participants in the Solicitation
Aviragen and Vaxart and their respective directors and officers
and certain of their other members of management and employees may
be deemed to be participants in the solicitation of proxies from
the stockholders of Aviragen in connection with the proposed
transaction. Information regarding the special interests of these
directors and executive officers in the merger are included in the
proxy statement/prospectus referred to above. Additional
information regarding the directors and executive officers of
Aviragen is also included in Aviragen’s Annual Report on Forms 10-K
for the year ended June 30, 2017, filed with the SEC on September
1, 2017, and the Form 10-K/A filed with the SEC on October 20,
2017. These documents are available free of charge from the sources
indicated above.
Contacts
Mark ColonneseExecutive Vice President and Chief Financial
OfficerAviragen Therapeutics, Inc.(678)
221-3381
mcolonnese@aviragentherapeutics.com
Beth DelGiaccoStern Investor Relations, Inc.(212)
362-1200beth@sternir.com
Kristian KleinD.F. King & Co., Inc.(212) 232-2247
Winnie Lerner / Nick LeasureFinsbury(646) 805-2855
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Sep 2023 to Sep 2024